A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–65
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female patients, 18-65 years of age
Histologically confirmed HER2-positive breast cancer with measurable lesions (according to RECIST criteria)
Metastatic disease after first-line therapy or recurrent disease after (neo)adjuvant therapy with Herceptin and taxanes
ECOG performance status 0-2
You may not be if
CNS metastases which are not well controlled
Simultaneous treatment with sorivudine
History of another malignancy within the last 5 years except for cured basal cell carcinoma of the skin and cured carcinoma in-situ of the uterine cervix
Pregnant or lactating women
Clareo Health | A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
